H. Jeffrey Wilkins

Dr. H. Jeffrey Wilkins is a Chief Medical Officer of Lycera. Dr. Wilkins brings over 15 years of clinical research experience, most recently serving as Clinical Lead and Partner of NeXeption, LLC, a biopharmaceutical management company. Previously, he was Chief Medical Officer and Head of Medical Affairs at Ceptaris Therapeutics, Inc., where he was the lead clinician on the successful NDA for VALCHLOR® gel, approved for the treatment of cutaneous T-cell lymphoma. Prior to this, Dr. Wilkins served as Vice President, Worldwide Clinical Research, Inflammation/Oncology at Cephalon Inc., where he led clinical development, medical affairs, and business development efforts in both therapeutic areas. Previously, he was Senior Vice President of Clinical Development with Caption Therapeutics, where he headed a successful program in eosinophilic asthma prior to the company’s acquisition by Cephalon. Dr. Wilkins entered the pharmaceutical industry joining GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s center of Excellence in External Drug Discovery. He also served as Group Director of GSK’s urology franchise, responsible for Levitra® and the launch of VESIcare®. Earlier in his career, Dr. Wilkins was Co-Founder and Chief Executive Officer of TriValley Primary Care, a large multi-center primary group in Pennsylvania.

Dr. Wilkins received his M.D. from Temple University and his B.S. from Bucknell University.